Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Buchanan

Showing results (551-560 of 594) with videos related to

Pageof 60
Sort By:
Biological Psychiatry|May 3, 2011
Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia II: developing imaging biomarkers to enhance treatment development for schizophrenia and related disordersCameron S Carter, Deanna M Barch, Edward Bullmore, et al.
The Journal of Clinical Psychiatry|December 7, 2007
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 updateTroy A Moore, Robert W Buchanan, Peter F Buckley, et al.
The American Journal of Psychiatry|April 3, 2008
Initial phase 2 trial of a nicotinic agonist in schizophreniaRobert Freedman, Ann Olincy, Robert W Buchanan, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|April 3, 2009
Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophreniaChristine E Marx, Richard S E Keefe, Robert W Buchanan, et al.
Journal of Psychiatric Research|March 25, 2014
The effect of artemether on psychotic symptoms and cognitive impairment in first-episode, antipsychotic drug-naive persons with schizophrenia seropositive to Toxoplasma gondiiHui-Ling Wang, Yu-Tao Xiang, Qiu-Ying Li, et al.
Molecular Autism|September 9, 2024
Task-based functional neural correlates of social cognition across autism and schizophrenia spectrum disordersLindsay D Oliver, Iska Moxon-Emre, Colin Hawco, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|January 18, 2013
Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophreniaL Fredrik Jarskog, Zhengchao Dong, Alayar Kangarlu, et al.
Schizophrenia Research|December 16, 2011
Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophreniaDaniel C Javitt, Robert W Buchanan, Richard S E Keefe, et al.
The Journal of Clinical Psychiatry|May 4, 2004
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 updateAlexander L Miller, Catherine S Hall, Robert W Buchanan, et al.
Archives of General Psychiatry|August 9, 2006
Genetic association and brain morphology studies and the chromosome 8p22 pericentriolar material 1 (PCM1) gene in susceptibility to schizophreniaHugh M D Gurling, Hugo Critchley, Susmita R Datta, et al.
Pageof 60

Showing results (551-560 of 594) with videos related to

Sort By:
Pageof 60
Biological Psychiatry|May 3, 2011
Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia II: developing imaging biomarkers to enhance treatment development for schizophrenia and related disordersCameron S Carter, Deanna M Barch, Edward Bullmore, et al.
The Journal of Clinical Psychiatry|December 7, 2007
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 updateTroy A Moore, Robert W Buchanan, Peter F Buckley, et al.
The American Journal of Psychiatry|April 3, 2008
Initial phase 2 trial of a nicotinic agonist in schizophreniaRobert Freedman, Ann Olincy, Robert W Buchanan, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|April 3, 2009
Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophreniaChristine E Marx, Richard S E Keefe, Robert W Buchanan, et al.
Journal of Psychiatric Research|March 25, 2014
The effect of artemether on psychotic symptoms and cognitive impairment in first-episode, antipsychotic drug-naive persons with schizophrenia seropositive to Toxoplasma gondiiHui-Ling Wang, Yu-Tao Xiang, Qiu-Ying Li, et al.
Molecular Autism|September 9, 2024
Task-based functional neural correlates of social cognition across autism and schizophrenia spectrum disordersLindsay D Oliver, Iska Moxon-Emre, Colin Hawco, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|January 18, 2013
Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophreniaL Fredrik Jarskog, Zhengchao Dong, Alayar Kangarlu, et al.
Schizophrenia Research|December 16, 2011
Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophreniaDaniel C Javitt, Robert W Buchanan, Richard S E Keefe, et al.
The Journal of Clinical Psychiatry|May 4, 2004
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 updateAlexander L Miller, Catherine S Hall, Robert W Buchanan, et al.
Archives of General Psychiatry|August 9, 2006
Genetic association and brain morphology studies and the chromosome 8p22 pericentriolar material 1 (PCM1) gene in susceptibility to schizophreniaHugh M D Gurling, Hugo Critchley, Susmita R Datta, et al.
Pageof 60